Key Details
Price
$1.86Annual ROE
-68.22%Beta
-0.16Events Calendar
Next earnings date:
May 14, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 30, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Jan 2, 2024Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
-- Interim data from Cohort 4 expected Q1 2025 -- MIAMI, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced it has opened three clinical trial sites in Eastern Europe. These sites in Romania and Bulgaria are actively recruiting patients along with the four open sites in the United States, for Pasithea's PAS-004 Phase 1 trial.
Pasithea completes chronic toxicity studies for PAS-004, showing safety and potential for long-term use in NF1 and cancer treatment; Phase 1 trial ongoing
Pasithea Tx appoints Dr. Rebecca Brown, an expert in Neurofibromatosis and Director at Mount Sinai, to its Scientific Advisory Board to aid in PAS-004.
Pasithea Therapeutics (NASDAQ: KTTA ) stock is falling on Wednesday after the company's shares experienced major volatility on Tuesday. Investors watching KTTA stock will note that it closed out Tuesday up less than 1%.
-- Attendees may request 1 x 1 meeting with management at [email protected] -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, announced today that Pasithea's management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference, to be held in New York City, September 11-13.
FAQ
- What is the ticker symbol for Pasithea Therapeutics?
- Does Pasithea Therapeutics pay dividends?
- What sector is Pasithea Therapeutics in?
- What industry is Pasithea Therapeutics in?
- What country is Pasithea Therapeutics based in?
- When did Pasithea Therapeutics go public?
- Is Pasithea Therapeutics in the S&P 500?
- Is Pasithea Therapeutics in the NASDAQ 100?
- Is Pasithea Therapeutics in the Dow Jones?
- When was Pasithea Therapeutics's last earnings report?
- When does Pasithea Therapeutics report earnings?
- Should I buy Pasithea Therapeutics stock now?